vs
Side-by-side financial comparison of HAEMONETICS CORP (HAE) and Palomar Holdings, Inc. (PLMR). Click either name above to swap in a different company.
HAEMONETICS CORP is the larger business by last-quarter revenue ($339.0M vs $253.4M, roughly 1.3× Palomar Holdings, Inc.). On growth, Palomar Holdings, Inc. posted the faster year-over-year revenue change (62.7% vs -2.7%). Palomar Holdings, Inc. produced more free cash flow last quarter ($409.0M vs $87.2M). Over the past eight quarters, Palomar Holdings, Inc.'s revenue compounded faster (46.2% CAGR vs 0.4%).
Haemonetics Corporation is a global provider of blood and plasma supplies and services. The company was founded in Natick, Massachusetts by Dr. Allen (Jack) Latham in the 1970s.
Palomar Holdings, Inc. is a specialty insurance holding company that primarily provides property insurance products for catastrophe-exposed residential and commercial assets. It mainly operates across the United States, focusing on core segments including earthquake, flood, and windstorm coverage to meet high-risk property protection demands of customers.
HAE vs PLMR — Head-to-Head
Income Statement — Q3 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $339.0M | $253.4M |
| Net Profit | $44.7M | — |
| Gross Margin | 59.7% | — |
| Operating Margin | 19.9% | 28.7% |
| Net Margin | 13.2% | — |
| Revenue YoY | -2.7% | 62.7% |
| Net Profit YoY | 19.3% | — |
| EPS (diluted) | $0.95 | $2.05 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $339.0M | $253.4M | ||
| Q3 25 | $327.3M | $244.7M | ||
| Q2 25 | $321.4M | $203.3M | ||
| Q1 25 | $330.6M | $174.6M | ||
| Q4 24 | $348.5M | $155.8M | ||
| Q3 24 | $345.5M | $148.5M | ||
| Q2 24 | $336.2M | $131.1M | ||
| Q1 24 | — | $118.5M |
| Q4 25 | $44.7M | — | ||
| Q3 25 | $38.7M | $51.5M | ||
| Q2 25 | $34.0M | $46.5M | ||
| Q1 25 | $58.0M | $42.9M | ||
| Q4 24 | $37.5M | — | ||
| Q3 24 | $33.8M | $30.5M | ||
| Q2 24 | $38.4M | $25.7M | ||
| Q1 24 | — | $26.4M |
| Q4 25 | 59.7% | — | ||
| Q3 25 | 59.5% | — | ||
| Q2 25 | 59.8% | — | ||
| Q1 25 | 58.4% | — | ||
| Q4 24 | 55.5% | — | ||
| Q3 24 | 54.2% | — | ||
| Q2 24 | 52.0% | — | ||
| Q1 24 | — | — |
| Q4 25 | 19.9% | 28.7% | ||
| Q3 25 | 17.9% | 27.4% | ||
| Q2 25 | 16.8% | 29.5% | ||
| Q1 25 | 21.6% | 30.8% | ||
| Q4 24 | 16.9% | 28.9% | ||
| Q3 24 | 15.0% | 25.9% | ||
| Q2 24 | 11.8% | 25.5% | ||
| Q1 24 | — | 29.0% |
| Q4 25 | 13.2% | — | ||
| Q3 25 | 11.8% | 21.0% | ||
| Q2 25 | 10.6% | 22.9% | ||
| Q1 25 | 17.5% | 24.6% | ||
| Q4 24 | 10.8% | — | ||
| Q3 24 | 9.8% | 20.5% | ||
| Q2 24 | 11.4% | 19.6% | ||
| Q1 24 | — | 22.3% |
| Q4 25 | $0.95 | $2.05 | ||
| Q3 25 | $0.81 | $1.87 | ||
| Q2 25 | $0.70 | $1.68 | ||
| Q1 25 | $1.17 | $1.57 | ||
| Q4 24 | $0.74 | $1.29 | ||
| Q3 24 | $0.66 | $1.15 | ||
| Q2 24 | $0.74 | $1.00 | ||
| Q1 24 | — | $1.04 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $363.4M | $106.9M |
| Total DebtLower is stronger | $1.2B | — |
| Stockholders' EquityBook value | $911.5M | $942.7M |
| Total Assets | $2.5B | $3.1B |
| Debt / EquityLower = less leverage | 1.34× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $363.4M | $106.9M | ||
| Q3 25 | $296.4M | $111.7M | ||
| Q2 25 | $292.9M | $81.3M | ||
| Q1 25 | $306.8M | $119.3M | ||
| Q4 24 | $320.8M | $80.4M | ||
| Q3 24 | $299.3M | $86.5M | ||
| Q2 24 | $344.4M | $47.8M | ||
| Q1 24 | — | $61.4M |
| Q4 25 | $1.2B | — | ||
| Q3 25 | $1.2B | — | ||
| Q2 25 | $1.2B | — | ||
| Q1 25 | $1.2B | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $911.5M | $942.7M | ||
| Q3 25 | $849.2M | $878.1M | ||
| Q2 25 | $882.3M | $847.2M | ||
| Q1 25 | $820.8M | $790.4M | ||
| Q4 24 | $906.9M | $729.0M | ||
| Q3 24 | $878.9M | $703.3M | ||
| Q2 24 | $905.4M | $532.6M | ||
| Q1 24 | — | $501.7M |
| Q4 25 | $2.5B | $3.1B | ||
| Q3 25 | $2.4B | $2.9B | ||
| Q2 25 | $2.5B | $2.8B | ||
| Q1 25 | $2.5B | $2.4B | ||
| Q4 24 | $2.5B | $2.3B | ||
| Q3 24 | $2.5B | $2.3B | ||
| Q2 24 | $2.5B | $2.0B | ||
| Q1 24 | — | $1.9B |
| Q4 25 | 1.34× | — | ||
| Q3 25 | 1.44× | — | ||
| Q2 25 | 1.39× | — | ||
| Q1 25 | 1.49× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $93.6M | $409.1M |
| Free Cash FlowOCF − Capex | $87.2M | $409.0M |
| FCF MarginFCF / Revenue | 25.7% | 161.4% |
| Capex IntensityCapex / Revenue | 1.9% | 0.1% |
| Cash ConversionOCF / Net Profit | 2.09× | — |
| TTM Free Cash FlowTrailing 4 quarters | $308.1M | $700.6M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $93.6M | $409.1M | ||
| Q3 25 | $111.3M | $83.6M | ||
| Q2 25 | $17.4M | $120.9M | ||
| Q1 25 | $116.6M | $87.2M | ||
| Q4 24 | $43.8M | $261.2M | ||
| Q3 24 | $48.8M | $100.3M | ||
| Q2 24 | $-27.4M | $55.1M | ||
| Q1 24 | — | $33.1M |
| Q4 25 | $87.2M | $409.0M | ||
| Q3 25 | $106.3M | $83.6M | ||
| Q2 25 | $13.6M | $120.8M | ||
| Q1 25 | $100.9M | $87.1M | ||
| Q4 24 | $35.2M | $260.9M | ||
| Q3 24 | $39.4M | $100.1M | ||
| Q2 24 | $-33.1M | — | ||
| Q1 24 | — | — |
| Q4 25 | 25.7% | 161.4% | ||
| Q3 25 | 32.5% | 34.2% | ||
| Q2 25 | 4.2% | 59.4% | ||
| Q1 25 | 30.5% | 49.9% | ||
| Q4 24 | 10.1% | 167.5% | ||
| Q3 24 | 11.4% | 67.4% | ||
| Q2 24 | -9.8% | — | ||
| Q1 24 | — | — |
| Q4 25 | 1.9% | 0.1% | ||
| Q3 25 | 1.5% | 0.0% | ||
| Q2 25 | 1.2% | 0.0% | ||
| Q1 25 | 4.7% | 0.0% | ||
| Q4 24 | 2.5% | 0.2% | ||
| Q3 24 | 2.7% | 0.1% | ||
| Q2 24 | 1.7% | 0.0% | ||
| Q1 24 | — | 0.0% |
| Q4 25 | 2.09× | — | ||
| Q3 25 | 2.88× | 1.63× | ||
| Q2 25 | 0.51× | 2.60× | ||
| Q1 25 | 2.01× | 2.03× | ||
| Q4 24 | 1.17× | — | ||
| Q3 24 | 1.44× | 3.29× | ||
| Q2 24 | -0.71× | 2.14× | ||
| Q1 24 | — | 1.26× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
HAE
| Hospital | $143.5M | 42% |
| Plasma Productsand Services | $138.9M | 41% |
| Blood Center Productsand Services | $56.6M | 17% |
PLMR
Segment breakdown not available.
